In a vaccine production facility, no one can hear you scream. (OK, they probably can but where else can we use such an iconic sci-fi movie reference?). Influenza was a key theme in this issue, with experts exploring why the virus is seen as a “moving target” and how new breakthroughs in vaccines and vaccine manufacturing technology could help. We also report on a visit to the UK’s largest flu vaccine facilities.
Also in the issue: the impact of the energy crisis on pharma; clinical trials and Where’s Waldo?; and interviewing CEO of Travere Therapeutics, Eric Dube.
We celebrated our 2023 Power List, which features influential and inspirational leaders across small molecule, biopharmaceutical, and advanced medicine development and manufacture. Although the Power List shines a light on individuals making big waves and big decisions, it takes a “village” – sometimes a virtual city – to raise a therapeutic – which is why our April issue also showcased our Company of the Year Awards.
Did you know that we are accepting nominations for our 2024 Power List? Click here to nominate (available until January 12). You can also vote in the Company of the Year Awards until February 12.
Also in this issue: how CRISPR gene editing is affecting antibody manufacturers; the golden age of drug delivery; and an interview with Carl June.
Gotta love the beautiful contrast of the yellow and pink in this cover! With genome editing and CRISPR/Cas9 making waves in drug development, we asked experts about the hype, reality, and ethics of this growing field in a roundtable discussion. Featuring Rachel Haurwitz from Caribou Biosciences, Tirtha Chakraborty from Vor Biopharma, Linda De Jesus from IDT, and Eric Rhodes from ERS Genomics.
Also in this issue: how ocean waste was turned into pharmaceutical compounds; the dark art of crystallization for small molecules; and the dangers of dengue.
Antibody drug conjugates are the stars of this issue – and so are the experts who can tell us all about them! From complex design challenges to issues with linker stability, ADCs have faced many hurdles, but we could be at a turning point according to the experts we spoke with.
Also in this issue: an ode to the microbe; calling everyone to arms over the dangers of antimicrobial resistance; and the future of analytics in biopharma manufacturing.
Let’s break that glass ceiling! Women still struggle to reach leadership positions in all industries – including pharma. Now that we’ve acknowledged the issue, it's high time we overcome it. We speak to women about their experiences in leadership. If you’re interested in this topic, you can also watch this video roundtable discussion featuring IPS, Resilience, and Women in Bio.
Also in this issue: the challenge of climate change and pharma supply chains; what to ask your cell therapy partners; and drug development involving llamas.
The end of a year is a time for celebration for many of us and it’s no different at The Medicine Maker. We end the year by celebrating some of the top drug development and manufacturing technologies to hit the market over the course of 2023 – as nominated by readers. Check out the showcase here. You can also vote for your favorite technology.
Also in this issue: how machine learning is affecting oligonucleotide manufacturing; the challenges of drug development for Alzheimer’s; and an interview with ten23 health CEO Hanns-Christian Mahler.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
